Skip to main content

Table 2 Clinical characteristics of the study population based on aspirin regular use

From: Longitudinal analysis of healthy colon establishes aspirin as a suppressor of cancer-related epigenetic aging

Characteristics

No. subjects

Time point 1 (t1)a

Time point 2 (t2)b

 

Nonuserc

Long-term user (≥ 2 year)d

Nonuserc

Long-term user (≥ 2 year)d

 

14 (45%)

17 (55%)

11 (35%)

20 (65%)

Age

50–70 (median 50)

51–69 (median 60)

60–77 (median 60)

60–80 (median 70)

BMIe

 Normal (18.5–25)

6 (43%)

10 (59%)

3 (27%)

11 (55%)

 High (≥ 26)

8 (57%)

7 (41%)

8 (73%)

9 (45%)

Polyps

 No Polyps

5 (36%)

13 (76%)

10 (91%)

13 (65%)

 Yes

9 (64%)

4 (24%)

1 (9%)

7 (35%)

  Proximalf

3 (33%)

1 (25%)

0 (0%)

2 (29%)

  Distalg

6 (67%)

3 (35%)

1 (100%)

4 (57%)

  Proximal and distal

0 (0%)

0 (0%)

0 (0%)

1 (14%)

  1. Regular use defined as ≥ 2 tablets/week for ≥ 1 month
  2. aBaseline time point
  3. b10-year follow-up
  4. cNonuser: women who indicated that they did not use the aspirin ≥ 2 tablets/week for ≥ 1 month (“minimum level”)
  5. dLong-term user: women who indicated that they used the aspirin ≥ 2 tablets/week for ≥ 2 years
  6. eBMI: body mass index; height (cm) and weight (kg) were self-reported and BMI was calculated (kg/m2) from these variables
  7. fProximal: cecum
  8. gDistal: sigmoid colon